Hims & Hers is transforming telehealth with personalized medications, rapid subscription growth, and strong financials, ...

Hims & Hers Health (NYSE: HIMS) stock is on a downward trend on both macro trends and news about GLP-1s. But this is still a ...

Delving into the details, we found 11% of traders were bullish, while 66% showed bearish tendencies. Out of all the trades we ...

Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $28.15 which represents a slight increase of $0.55 or 1.99% from the prior close of $27.6. The stock opened at $27.97 and ...

Hims & Hers faces regulatory hurdles but shows strong business growth. Find out why HIMS stock is a "Hold" despite setbacks ...

The Short discusses a 15% drop in Hims & Hers stock following an FDA announcement ending the shortage of Eli Lilly's weight ...

CNBC’s Jim Cramer suggested on Tuesday that NVIDIA Corp. (NASDAQ:NVDA) may have reached a key turning point after the stock ...

Craig Hettenbach, an analyst from Morgan Stanley, maintained the Buy rating on Hims & Hers Health (HIMS – Research Report). The associated ...

Short HIMS slightly under 31.35, target 24.9, stop loss @ 31.44 Check the time stamp on this data. Updated AI-Generated ...

HIMS is on track for its worst single-session decline since Nov. 14, when Amazon.com (AMZN) entered the telehealth services ...

Hims stock skidded Thursday after the FDA determined Eli Lilly's tirzepatide — which sells as a weight-loss drug — is no ...

In terms of liquidity and interest, the mean open interest for Hims & Hers Health options trades today is 3348.53 with a ...